Ulinastatitis in Complex Treatment of Acute Pancreatitis (Literature Review)

Abstract

The purpose of this literature review is to assess the completeness and significance of recent research on the treatment of a destructive form of pancreatitis for public health and scientific achievements, highlighting areas that require further detailed study. A review of foreign literature on the use of the protease inhibitor ulinastatin in the complex conservative treatment and prevention of acute pancreatitis is made. The clinical and laboratory effectiveness of the drug in preventing the transition of uninfected pancreatic necrosis into a complicated purulent-necrotic form with the development of abdominal sepsis, as well as the effect on treatment results and mortality, has been demonstrated. Existing schemes and modes of application are given. In recent years, significant scientific achievements have been presented in the field of treatment of acute pancreatitis, especially in the context of its destructive forms. The results of numerous studies have made it possible to formulate recommendations aimed at optimizing treatment approaches and improving the prognosis of this condition. Studies have identified key factors affecting the prognosis and outcome of treatment of acute pancreatitis, including the degree of destruction of the pancreas, clinical and laboratory characteristics of patients, as well as complications associated with various treatment methods. These data will allow surgeons to develop individual treatment strategies, taking into account the specifics of each case. Ulinastatin is not only a protease inhibitor, but also has anti-inflammatory and immunomodulatory properties. Based on the results of numerous foreign studies, the high clinical and laboratory effectiveness of ulinastainin the complex drug therapy of acute pancreatitis has been proven. And also, to prevent it and/or hyperfermentemia during ERCP and extended operations on the organs of the pancreato-duodenal zone. Ulinastatin is most effective in the edematous form of AP and aseptic pancreatic necrosis. In case of infected pacreonecrosis with severe organ-systemic failure or the formation of purulent-necrotic foci in the retroperitoneum (abdominal sepsis), the drug is not effective.